

## Table of Contents

Follow this and additional works at: <http://scholarship.law.marquette.edu/iplr>



Part of the [Law Commons](#)

---

### Repository Citation

*Table of Contents*, 18 Intellectual Property L. Rev. (2014).

Available at: <http://scholarship.law.marquette.edu/iplr/vol18/iss1/9>

This Prefatory Matter is brought to you for free and open access by the Journals at Marquette Law Scholarly Commons. It has been accepted for inclusion in Marquette Intellectual Property Law Review by an authorized administrator of Marquette Law Scholarly Commons. For more information, please contact [megan.obrien@marquette.edu](mailto:megan.obrien@marquette.edu).

**MARQUETTE INTELLECTUAL PROPERTY  
LAW REVIEW**

---

Volume 18

Winter 2014

Number 1

---

**2013 ANNUAL HELEN WILSON NIES LECTURE**

DIAGNOSTIC PATENTS AT THE SUPREME COURT

*Arti K. Rai*..... 1

**INTELLECTUAL PROPERTY POLICY FORUM:  
PHARMACEUTICAL DEVELOPMENT AND HEALTHCARE  
INNOVATION**

FOREWORD FROM THE EDITORS ..... 13

TOMMY THOMPSON, *Drug Development – Translating Basic Research into  
New Medicines* ..... 15

G. STEVEN BURRILL, *Forward-looking View of Healthcare Innovation, from  
a Leading Life Science Venture Capitalist* ..... 17

DAVID MEININGER, *The Increasing Importance of Biologics-based Drugs in  
Pharmaceutical Pipelines* ..... 19

GARRET A. FITZGERALD, *Need for New IP Approaches to Facilitate  
Collaborative (Academic-Industrial) Drug Development*..... 21

BRUCE BLOOM, *New Business Models to Find Cures and Lower Healthcare  
Costs: A Role for Drug Repurposing* ..... 23

RAMAIAH MUTHYALA, *Repurposing & Collaborative Drug Development for  
Rare Diseases* ..... 25

HARSHA K. RAJASIMHA, *The Future of Clinical Trials: More Transparency  
and Pharmacogenomics* ..... 27

JOHN R. RAYMOND, *Implications of Genomics Advances for Drug Discovery,  
Clinical Therapies, & Rare Disease Research*..... 29

HUGH LAVERTY & MAGALI POINOT, *Intellectual Property Rights (IPR) in  
Collaborative Drug Development in the EU: Helping a European  
Public-Private Partnership Deliver – the Need for a Flexible Approach  
to IPR* ..... 31

*INTELLECTUAL PROPERTY POLICY FORUM ARTICLES*

A NEW FRAMEWORK FOR ASSESSING CLINICAL DATA TRANSPARENCY  
INITIATIVES

*Erika Lietzan*..... 33

ANCILLARY ORDERS OF COMPULSORY LICENSING AND THEIR  
COMPATIBILITY WITH THE TRIPS AGREEMENT

*Richard Li-dar Wang* ..... 87

*INTELLECTUAL PROPERTY POLICY FORUM COMMENTS*

THE NEW ERA OF BIOLOGIC REGULATION AND PATENTING UNDER THE  
AMERICA INVENTS ACT  
*David I. Rucker* ..... 107

REPURPOSING – FINDING NEW USES FOR OLD (AND PATENTED) DRUGS:  
BRIDGING THE “VALLEY OF DEATH,” TO TRANSLATE ACADEMIC  
RESEARCH INTO NEW MEDICINES  
*Daniel S. Sem*..... 139

**INTERNATIONAL INTELLECTUAL PROPERTY SCHOLARS  
SERIES**

TRADEMARKS UNDER THE NORTH AMERICAN FREE TRADE AGREEMENT  
(NAFTA), WITH REFERENCES TO THE CURRENT MEXICAN LAW  
*Roberto Rosas* ..... 167

**ARTICLES**

TERRITORIALITY CHALLENGES IN PROTECTING TRADEMARK INTERESTS  
IN THE SYSTEM OF GENERIC TOP-LEVEL DOMAINS (GTLDS)  
*Jesse Kim* ..... 217

**COMMENTS**

HOW MEDIA GOT THE BIGGEST BITE OF (THE) APPLE: A LOOK AT THE  
MEDIA MISPERCEPTION IN THE APPLE-SAMSUNG CASE  
*Neha Pathak*..... 237